Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qinghong Han

Showing results (41-50 of 143) with videos related to

Pageof 15
Sort By:
Biochemistry and Biophysics Reports|December 8, 2021
Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferationYusuke Aoki, Yasunori Tome, Qinghong Han, et al.
Cancer Genomics & Proteomics|March 4, 2023
Oncogenes and Methionine Addiction of Cancer: Role of <i>c-MYC</i>Yusuke Aoki, Qinghong Han, Yutaro Kubota, et al.
Anticancer Research|December 1, 2022
Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine RestrictionYutaro Kubota, Qinghong Han, Noriyuki Masaki, et al.
Biochemical and Biophysical Research Communications|January 4, 2024
Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable diseaseYutaro Kubota, Yusuke Aoki, Noriyuki Masaki, et al.
Cancer Diagnosis & Prognosis|May 4, 2026
The Combination of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 and Recombinant Methioninase Is Not Cancer-selective in a Co-culture Model of Colon Cancer Cells and Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|November 29, 2025
The Combination of Recombinant Methioninase and Low-dose Chloroquine Selectively Eradicates Colon-Cancer Cells Without Apparent Toxicity on Co-cultured Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|December 30, 2025
Effect of Recombinant Methioninase Dose and Timing on the Selective and Precise Elimination of Cancer Cells from Co-Cultured Normal Cells and on Methionine-dependent Rescue of Cancer CellsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|October 28, 2025
Simultaneous Targeting of Multiple Hallmarks of Cancer With Recombinant Methioninase, Rapamycin and Chloroquine Is Specific and Synergistic to MiaPaCa-2 Pancreatic-Cancer Cells in Contrast to Hs-27 Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Cancer Diagnosis & Prognosis|November 6, 2023
Recombinant Methioninase Lowers the Effective Dose of Regorafenib Against Colon-Cancer Cells: A Strategy for Widespread Clinical Use of a Toxic DrugBrad Barsam Choobin, Yutaro Kubota, Qinghong Han, et al.
Anticancer Research|January 30, 2026
Lack of Cancer Specificity of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 in Combination With Recombinant Methioninase <i>In Vitro</i>Jinsoo Kim, Qinghong Han, Shukuan Li, et al.
Pageof 15

Showing results (41-50 of 143) with videos related to

Sort By:
Pageof 15
Biochemistry and Biophysics Reports|December 8, 2021
Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferationYusuke Aoki, Yasunori Tome, Qinghong Han, et al.
Cancer Genomics & Proteomics|March 4, 2023
Oncogenes and Methionine Addiction of Cancer: Role of <i>c-MYC</i>Yusuke Aoki, Qinghong Han, Yutaro Kubota, et al.
Anticancer Research|December 1, 2022
Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine RestrictionYutaro Kubota, Qinghong Han, Noriyuki Masaki, et al.
Biochemical and Biophysical Research Communications|January 4, 2024
Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable diseaseYutaro Kubota, Yusuke Aoki, Noriyuki Masaki, et al.
Cancer Diagnosis & Prognosis|May 4, 2026
The Combination of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 and Recombinant Methioninase Is Not Cancer-selective in a Co-culture Model of Colon Cancer Cells and Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|November 29, 2025
The Combination of Recombinant Methioninase and Low-dose Chloroquine Selectively Eradicates Colon-Cancer Cells Without Apparent Toxicity on Co-cultured Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|December 30, 2025
Effect of Recombinant Methioninase Dose and Timing on the Selective and Precise Elimination of Cancer Cells from Co-Cultured Normal Cells and on Methionine-dependent Rescue of Cancer CellsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Anticancer Research|October 28, 2025
Simultaneous Targeting of Multiple Hallmarks of Cancer With Recombinant Methioninase, Rapamycin and Chloroquine Is Specific and Synergistic to MiaPaCa-2 Pancreatic-Cancer Cells in Contrast to Hs-27 Normal FibroblastsJinsoo Kim, Qinghong Han, Shukuan Li, et al.
Cancer Diagnosis & Prognosis|November 6, 2023
Recombinant Methioninase Lowers the Effective Dose of Regorafenib Against Colon-Cancer Cells: A Strategy for Widespread Clinical Use of a Toxic DrugBrad Barsam Choobin, Yutaro Kubota, Qinghong Han, et al.
Anticancer Research|January 30, 2026
Lack of Cancer Specificity of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 in Combination With Recombinant Methioninase <i>In Vitro</i>Jinsoo Kim, Qinghong Han, Shukuan Li, et al.
Pageof 15